Skip to main content
Top
Published in: Journal of Gastrointestinal Surgery 7/2019

01-07-2019 | Antireflux Surgery | Original Article

Can Impedance-pH Testing on Medications Reliably Identify Patients with GERD as Defined by Pathologic Esophageal Acid Exposure off Medications?

Authors: Marc A. Ward, Christy M. Dunst, Matthew E. Glasgow, Ezra N. Teitelbaum, Walaa F. Abdelmoaty, Kevin M. Reavis, Lee L. Swanstrӧm, Steven R. DeMeester

Published in: Journal of Gastrointestinal Surgery | Issue 7/2019

Login to get access

Abstract

Introduction

Impedance-pH testing (MII-pH) while patients are on acid suppression medications is frequently used to evaluate persistent reflux symptoms. The aim of this study was to determine whether MII-pH on medications can reliably identify patients with gastroesophageal reflux disease (GERD) as defined by pathologic esophageal acid exposure off medications, and to determine if there is a threshold of total reflux episodes on medications where pH testing off medications may be unnecessary.

Methods

A retrospective review identified all patients between 1/2010 and 4/2017 who underwent MII-pH testing on PPI medications and subsequently had pH testing off medications. GERD was defined on pH testing off medications by an abnormal DeMeester Score (DMS) and on MII-pH on medications by ≥ 48 total reflux episodes. Patients with an abnormal DMS by MII-pH on medications were excluded.

Results

There were 71 patients, (22 males; 49 females), with a median age of 52 years. Based on ≥ 48 total reflux episodes by MII-pH testing on medications, 42 patients (59%) had GERD. When tested off medications, an abnormal DMS was present in 44 patients (62%). Among those with GERD based on impedance testing on medications, 31% did not have GERD based on pH testing off medications. Further, in the 29 patients with ≤ 48 total reflux episodes on MII-pH (normal test), 15 patients (52%) had pathologic acid exposure off medications. When there were > 73 reflux events with MII-pH on medications, all 15 patients in our series had pathologic acid exposure on pH testing off medications.

Conclusion

MII-pH testing on medications in patients with refractory GERD symptoms does not reliably correlate with a diagnosis of GERD as defined by pathologic esophageal acid exposure off medications. The commonly used abnormal MII-pH test value of ≥ 48 total reflux episodes is not validated and should not be used. However, in our series, patients with > 73 total reflux episodes had a high likelihood of having pathologic acid exposure off medications. Overall, the preferred strategy to evaluate patients with persistent GERD symptoms on acid suppression therapy should be pH testing off medications.
Literature
2.
go back to reference Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003; 98:1940–4.CrossRefPubMed Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003; 98:1940–4.CrossRefPubMed
3.
go back to reference Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383–1413.CrossRefPubMed Kahrilas PJ, Shaheen NJ, Vaezi MF. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008;135:1383–1413.CrossRefPubMed
4.
go back to reference Kenneth R. DeVault DOC. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190–200.CrossRef Kenneth R. DeVault DOC. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190–200.CrossRef
5.
6.
go back to reference Silny J. Intraluminal multiple electric impedance procedure for measurement of gastrointestinal motility. J Gastrointest Motil 1991;3:151–62.CrossRef Silny J. Intraluminal multiple electric impedance procedure for measurement of gastrointestinal motility. J Gastrointest Motil 1991;3:151–62.CrossRef
7.
go back to reference Tutuian R, Castell D. Review article: complete gastro-oesophageal reflux monitoring—combined pH and impedance. Aliment Pharmacol Ther 2006;24(Suppl 2):27–37.CrossRefPubMed Tutuian R, Castell D. Review article: complete gastro-oesophageal reflux monitoring—combined pH and impedance. Aliment Pharmacol Ther 2006;24(Suppl 2):27–37.CrossRefPubMed
8.
go back to reference Agrawal A, Castell D. Clinical importance of impedance measurements. J Clin Gastroenterol 2008;42:579–583.CrossRefPubMed Agrawal A, Castell D. Clinical importance of impedance measurements. J Clin Gastroenterol 2008;42:579–583.CrossRefPubMed
9.
go back to reference Sifrim D, Blondeau K. Technology insight: the role of impedance testing for esophageal disorders. Nat Clin Pract Gastroenterol Hepatol 2006 1;3:210–219.CrossRef Sifrim D, Blondeau K. Technology insight: the role of impedance testing for esophageal disorders. Nat Clin Pract Gastroenterol Hepatol 2006 1;3:210–219.CrossRef
10.
go back to reference Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastro. 2003 Dec 30;99(6):1037–1043.CrossRef Shay S, Tutuian R, Sifrim D, et al. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastro. 2003 Dec 30;99(6):1037–1043.CrossRef
11.
go back to reference Zerbib F, des Varannes S, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian; French cohort of healthy subjects. Aliment Pharmacol Ther 2005;22:1011–1021.CrossRefPubMed Zerbib F, des Varannes S, Roman S, et al. Normal values and day-to-day variability of 24-h ambulatory oesophageal impedance-pH monitoring in a Belgian; French cohort of healthy subjects. Aliment Pharmacol Ther 2005;22:1011–1021.CrossRefPubMed
12.
go back to reference Zentilin P, Iiritano E, Dulbecco P, Bilardi C, Savarino E, De Conca S, Parodi A, Reglioni S, Vigneri S, Savarino V. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Digestive and liver disease. 2006 Apr 30;38(4):226–32.CrossRefPubMed Zentilin P, Iiritano E, Dulbecco P, Bilardi C, Savarino E, De Conca S, Parodi A, Reglioni S, Vigneri S, Savarino V. Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. Digestive and liver disease. 2006 Apr 30;38(4):226–32.CrossRefPubMed
13.
go back to reference Xiao YL, Lin JK, Cheung TK, Wong NY, Yang L, Hung IF, Wong BC, Chen MH. Normal values of 24-hour combined esophageal multichannel intraluminal impedance and pH monitoring in the Chinese population. Digestion. 2009 Mar 18;79(2):109–14.CrossRefPubMed Xiao YL, Lin JK, Cheung TK, Wong NY, Yang L, Hung IF, Wong BC, Chen MH. Normal values of 24-hour combined esophageal multichannel intraluminal impedance and pH monitoring in the Chinese population. Digestion. 2009 Mar 18;79(2):109–14.CrossRefPubMed
14.
go back to reference Zerbib F, Roman S, Des Varannes SB, Gourcerol G, Coffin B, Ropert A, Lepicard P, Mion F, De Neuro-Gastroentérologie GF. Normal values of pharyngeal and esophageal 24-hour pH impedance in individuals on and off therapy and interobserver reproducibility. Clinical Gastroenterology and Hepatology. 2013 Apr 30;11(4):366–72.CrossRefPubMed Zerbib F, Roman S, Des Varannes SB, Gourcerol G, Coffin B, Ropert A, Lepicard P, Mion F, De Neuro-Gastroentérologie GF. Normal values of pharyngeal and esophageal 24-hour pH impedance in individuals on and off therapy and interobserver reproducibility. Clinical Gastroenterology and Hepatology. 2013 Apr 30;11(4):366–72.CrossRefPubMed
15.
go back to reference Doulami G, Triantafyllou S, Natoudi M, Albanopoulos K, Menenakos E, Filis K, Zografos G, Theodorou D. Normal Values of 24H Multichannel Intraluminal Impedance pH-Metry in a Greek Obese Population Based on Montreal Definition of Gerd. Obesity surgery. 2016 Jan 1;26(1):126–31.CrossRefPubMed Doulami G, Triantafyllou S, Natoudi M, Albanopoulos K, Menenakos E, Filis K, Zografos G, Theodorou D. Normal Values of 24H Multichannel Intraluminal Impedance pH-Metry in a Greek Obese Population Based on Montreal Definition of Gerd. Obesity surgery. 2016 Jan 1;26(1):126–31.CrossRefPubMed
16.
go back to reference Slaughter JC, Goutte M, Rymer JA, Oranu AC, Schneider JA, Garrett CG, Hagaman D, Vaezi MF. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clinical Gastroenterology and Hepatology. 2011 Oct 1;9(10):868–74.CrossRefPubMed Slaughter JC, Goutte M, Rymer JA, Oranu AC, Schneider JA, Garrett CG, Hagaman D, Vaezi MF. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clinical Gastroenterology and Hepatology. 2011 Oct 1;9(10):868–74.CrossRefPubMed
17.
go back to reference Tutuian R, Mainie I, Agrawal A, et al. Normal values for ambulatory 24-h combined impedance-pH monitoring on acid suppressive therapy. Gastroenterology 2006;130(Suppl 2):A171. Tutuian R, Mainie I, Agrawal A, et al. Normal values for ambulatory 24-h combined impedance-pH monitoring on acid suppressive therapy. Gastroenterology 2006;130(Suppl 2):A171.
18.
go back to reference Pandolfino J, Richter J, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003;98:740–749.CrossRefPubMed Pandolfino J, Richter J, Ours T, et al. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003;98:740–749.CrossRefPubMed
19.
go back to reference Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. The Am J Gastro. 2006 Aug 1;101(8):1900–20.CrossRef Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. The Am J Gastro. 2006 Aug 1;101(8):1900–20.CrossRef
20.
go back to reference Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575–83.CrossRefPubMed Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575–83.CrossRefPubMed
21.
go back to reference Ayazi S, Lipham JC, Portale G, Peyre CG, Streets CG, Leers JM, DeMeester SR, Banki F, Chan LS, Hagen JA, DeMeester TR. Bravo catheter-free pH monitoring: normal values, concordance, optimal diagnostic thresholds, and accuracy. Clinical Gastroenterology and Hepatology. 2009 Jan 31;7(1):60–7.CrossRefPubMed Ayazi S, Lipham JC, Portale G, Peyre CG, Streets CG, Leers JM, DeMeester SR, Banki F, Chan LS, Hagen JA, DeMeester TR. Bravo catheter-free pH monitoring: normal values, concordance, optimal diagnostic thresholds, and accuracy. Clinical Gastroenterology and Hepatology. 2009 Jan 31;7(1):60–7.CrossRefPubMed
22.
go back to reference Moawad FJ, Betteridge JD, Boger JA, Cheng FK, Belle LS, Chen YJ, Maydonovitch CL, Wong RK. Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study. Alimentary pharmacology & therapeutics. 2013 May 1;37(10):1011–8.CrossRef Moawad FJ, Betteridge JD, Boger JA, Cheng FK, Belle LS, Chen YJ, Maydonovitch CL, Wong RK. Reflux episodes detected by impedance in patients on and off esomeprazole: a randomised double-blinded placebo-controlled crossover study. Alimentary pharmacology & therapeutics. 2013 May 1;37(10):1011–8.CrossRef
23.
go back to reference Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG, Vaezi MF. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clinical Gastroenterology and Hepatology. 2009 Jul 1;7(7):743–8.CrossRefPubMed Pritchett JM, Aslam M, Slaughter JC, Ness RM, Garrett CG, Vaezi MF. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy. Clinical Gastroenterology and Hepatology. 2009 Jul 1;7(7):743–8.CrossRefPubMed
24.
go back to reference Herregods TV, Troelstra M, Weijenborg PW, Bredenoord AJ, Smout AJ. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterology & Motility. 2015 Sep 1;27(9):1267–73.CrossRef Herregods TV, Troelstra M, Weijenborg PW, Bredenoord AJ, Smout AJ. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterology & Motility. 2015 Sep 1;27(9):1267–73.CrossRef
25.
go back to reference Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. The American journal of gastroenterology. 2012 Jul 1;107(7):1001–10.CrossRefPubMed Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. The American journal of gastroenterology. 2012 Jul 1;107(7):1001–10.CrossRefPubMed
26.
go back to reference Hsu WT, Lai CC, Wang YH, Tseng PH, Wang K, Wang CY, Chen L. Risk of pneumonia in patients with gastroesophageal reflux disease: A population-based cohort study. PloS one. 2017 Aug 24;12(8):e0183808.CrossRefPubMedPubMedCentral Hsu WT, Lai CC, Wang YH, Tseng PH, Wang K, Wang CY, Chen L. Risk of pneumonia in patients with gastroesophageal reflux disease: A population-based cohort study. PloS one. 2017 Aug 24;12(8):e0183808.CrossRefPubMedPubMedCentral
27.
go back to reference Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Jama. 2013 Dec 11;310(22):2435–42.CrossRefPubMed Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. Jama. 2013 Dec 11;310(22):2435–42.CrossRefPubMed
28.
go back to reference Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based from the Canadian Multicentre Osteoporosis Study (CaMos). The American journal of gastroenterology. 2012 Sep 1;107(9):1361–9.CrossRefPubMedPubMedCentral Targownik LE, Leslie WD, Davison KS, Goltzman D, Jamal SA, Kreiger N, Josse RG, Kaiser SM, Kovacs CS, Prior JC, Zhou W. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based from the Canadian Multicentre Osteoporosis Study (CaMos). The American journal of gastroenterology. 2012 Sep 1;107(9):1361–9.CrossRefPubMedPubMedCentral
29.
go back to reference Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms:‘on’or ‘off’proton pump inhibitor?. The American journal of gastroenterology. 2008 Oct 1;103(10):2446–53.CrossRefPubMed Hemmink GJ, Bredenoord AJ, Weusten BL, Monkelbaan JF, Timmer R, Smout AJ. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms:‘on’or ‘off’proton pump inhibitor?. The American journal of gastroenterology. 2008 Oct 1;103(10):2446–53.CrossRefPubMed
Metadata
Title
Can Impedance-pH Testing on Medications Reliably Identify Patients with GERD as Defined by Pathologic Esophageal Acid Exposure off Medications?
Authors
Marc A. Ward
Christy M. Dunst
Matthew E. Glasgow
Ezra N. Teitelbaum
Walaa F. Abdelmoaty
Kevin M. Reavis
Lee L. Swanstrӧm
Steven R. DeMeester
Publication date
01-07-2019
Publisher
Springer US
Published in
Journal of Gastrointestinal Surgery / Issue 7/2019
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-019-04148-6

Other articles of this Issue 7/2019

Journal of Gastrointestinal Surgery 7/2019 Go to the issue